TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404775
Drug: mastalgia-oil placebo, tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
Study: NCT05907122
Drug: ABP 206
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
Study: NCT05907122
Drug: FDA-licensed Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Study: NCT05907122
Drug: EU-authorized Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Study: NCT06541314
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.
Study: NCT06041386
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab will be prescribed based on physician decision.
Study: NCT05479578
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04203316
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04203316
Drug: Enasidenib Mesylate
Normalized name: Enasidenib Mesylate
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06215261
Drug: Methylone
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)
Study: NCT05639946
Drug: brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
Study: NCT05926336
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Study: NCT05926336
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study: NCT06205199
Drug: Hydromorphone was injected into the subarachnoid space
Normalized name: hydromorphone Injection
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of hydromorphone is 50 micrograms
Study: NCT05224141
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
Study: NCT05224141
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study: NCT05224141
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study: NCT05898841
Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
Study: NCT05898841
Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day
Normalized name: emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG [Odefsey]
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
Study: NCT05241431
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg orally once daily in addition to standard medical treatment.
Study: NCT04680676
Drug: BI 730357
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 730357
Study: NCT00000656
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000656
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05821712
Drug: 0.057% sodium fluoride Mouthwash
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mouthwash
Study: NCT05443555
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
Study: NCT04974047
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as specified in the treatment arm.
Study: NCT05898841
Drug: Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
Study: NCT05890976
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide tablets orally once daily for 44 weeks.
Study: NCT05890976
Drug: Semaglutide Placebo
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive placebo matched to semaglutide.
Study: NCT05802173
Drug: TDM-105795 topical vehicle solution
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study: NCT06005974
Drug: REC-4881
Normalized name: REC-994
DrugBank: REC-994 (DB15616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REC-4881 4mg capsules
Study: NCT05265052
Drug: 3D1002 (50 mg)(Phase IIa)
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of 3D1002 per oral dose
Study: NCT05265052
Drug: 3D1002 (100 mg)(Phase IIa)
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 3D1002 per oral dose
Study: NCT05265052
Drug: 3D1002 (150 mg)(Phase IIa)
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of 3D1002 per oral dose
Study: NCT05265052
Drug: 3D1002 monotherapy (Phase IIb)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D1002 is administered at recommended dose with mimic OxyContin tablets.
Study: NCT05265052
Drug: OxyContin monotherapy (Phase IIb)
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
Study: NCT05265052
Drug: 3D1002 + OxyContin (Phase IIb)
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Study: NCT06395688
Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
Normalized name: Pregn-4-ene-3,20-dione
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AEF0117 soft capsules of 1mg
Study: NCT05760612
Drug: Trastuzumab and nelatinib
Normalized name: pertuzumab and trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Postoperative adjuvant treatment, for about 1 year
Study: NCT05760612
Drug: Trastuzumab and Parstuzumab
Normalized name: pertuzumab and trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Postoperative adjuvant treatment, for about 1 year
Study: NCT05573386
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
Study: NCT05573386
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
Study: NCT04877717
Drug: SHR-A1904
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1904
Study: NCT04696042
Drug: Lanreotide autogel
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide autogel 90-120 mcg, every 4 weeks
Study: NCT05350592
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single bolus
Study: NCT06233110
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
Study: NCT05350592
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continous weight-adjusted infusion
Study: NCT05930951
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
Study: NCT06233110
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
Study: NCT05906706
Drug: dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) administration
Study: NCT05113394
Drug: HDM sublingual Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
Study: NCT06384261
Drug: Cusatuzumab
Normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD70 monoclonal antibody
Study: NCT06384261
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCL-2 inhibitor
Study: NCT06384261
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Hypomethylating agent
Study: NCT06466382
Drug: Carboplatin / Paclitaxel Chemotherapy
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly
Study: NCT04953052
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An isotonic sterile solution of imatinib.
Study: NCT05329090
Drug: Rituximab Injection
Normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
Study: NCT06412315
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
Study: NCT06513884
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
Study: NCT05470101
Drug: ITI-333
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-333 oral solution
Study: NCT05440708
Drug: TTI-101
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05440708
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT05440708
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT05440708
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT05048082
Drug: pegsitacianine
Normalized name: Pegsitacianine
DrugBank: Pegsitacianine (DB19098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Study: NCT05913388
Drug: GB1211
Normalized name: GB1211
DrugBank: GB1211 (DB17499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice daily at 100mg.
Study: NCT05913388
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered at a fixed dose of 200 mg every 3 weeks intravenously.
Study: NCT05482672
Drug: Fisetin
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
Study: NCT05188222
Drug: Maltodextrin solution
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
Study: NCT06547203
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks
Study: NCT05613036
Drug: BI 907828
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 907828
Study: NCT06161974
Drug: Olutasidenib + TMZ
Normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
Study: NCT06547203
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
Study: NCT06547203
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
Study: NCT04818151
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin treatment for VTE
Study: NCT04818151
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban treatment for VTE
Study: NCT05223231
Drug: anti-PD-1 antibody injection
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: provide medicine base on needs
Study: NCT05716009
Drug: Dose Escalation -tagraxofusp-erzs
Normalized name: tagraxofusp-erzs
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
Study: NCT05716009
Drug: Dose Expansion at RP2D -tagraxofusp-erzs
Normalized name: tagraxofusp-erzs
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
Study: NCT00021671
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021671
Drug: Ampicillin sodium
Normalized name: Ampicillin Sodium
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021671
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06241456
Drug: FT825
Normalized name: Fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
Study: NCT06241456
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an IV infusion at planned dose levels.
Study: NCT06241456
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Study: NCT06241456
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered as an IV infusion at planned dose levels.
Study: NCT06241456
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered as an IV infusion at planned dose levels.
Study: NCT06241456
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered as an IV infusion at planned dose levels.
Study: NCT05461339
Drug: TAB014 Monoclonal Antibody Injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection at 1.25mg once every 4 weeks
Study: NCT05461339
Drug: Ranibizumab Injection [Lucentis]
Normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection at 0.5mg once every 4 weeks
Study: NCT06458400
Drug: Tegileridine
Normalized name: Tegileridine
DrugBank: Tegileridine (DB18988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose+PCA dose
Study: NCT06458400
Drug: Oliceridine
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose+PCA dose
Study: NCT06458400
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose+PCA dose
Study: NCT06530563
Drug: Oliceridine Injection [Olinvyk]
Normalized name: oliceridine Injection [Olinvyk]
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.
Study: NCT05185115
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
Study: NCT04966741
Drug: Setmelanotide
Normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC injection once daily.
Study: NCT06100289
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV injection.